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PrognosisSummary Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is cytologically and phenotyp-
ically heterogeneous. Retinoic acid–related orphan receptor-γt (RORγt) is a transcription factor that regu-
lates the differentiation of naïve CD4+ helper T cells to Th17 cells. In the present study, we
immunohistochemically confirmed the expression of RORγt in PTCL-NOS. Pathological and clinical inves-
tigations were performed for 170 cases of PTCL-NOS. RORγt-positive cases accounted for 17.6% (30/170)
of the total cases, and they showed a significantly higher frequency of CD8 positivity (P = .033), lower
counts of white blood cells (P = .030) and neutrophils (P = .039) in the peripheral blood, higher levels of
hypergammaglobulinemia (P = .031), a higher frequency of a complete response (P = .009), and a tendency
for a lower International Prognostic Index (P = .061) and better overall survival (P = .0806). These results
suggest that RORγt-positive PTCL-NOS could be a subpopulation of PTCL-NOS. Further research associ-
ated with this genomic abnormality at the transcriptional level is needed to confirm the results of this study.
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Peripheral T-cell lymphoma, not otherwise specified
(PTCL-NOS) is a diverse, yet common subtype of peripheral
T-cell lymphomas and natural killer/T-cell lymphomas, ac-
counting for approximately 30% and 25% of all T-cell lym-
phomas in Western and Asian countries, respectively [1-3].
PTCL-NOS is cytologically and phenotypically heteroge-
neous and has a poor prognosis, with a 5-year overall survival
(OS) of 32% [3].
87RORγt in PTCL-NOSRetinoic acid–related orphan receptor-γt (RORγt) is a nuclear
transcription factor that regulates the differentiation of naiveCD4+
T helper cells to interleukin (IL)-17–secreting Th17 cells [4].
IL-17 is a proinflammatory cytokine and, like all members of
the IL-17 family, plays an important role in inflammatory dis-
eases [5]. The expression of RORγt has been studied in several
cancers, including melanoma and colon cancer [6,7]. The as-
sociation between RORγt expression and prognosis varies in
different cancers. The expression of nuclear transcription fac-
tors, including RORγt, has been examined in a small number
of PTCL-NOS cases; however, a study linking it to clinical in-
formation, including prognosis, has not been performed [8].
The differentiation of naive CD4+ T helper cells into other ef-
fector T cells, such as Th1, Th2, Treg, and T follicular helper
(Tfh) cells, is regulated by various transcription factors, such
as T-Bet for Th1, GATA binding protein 3 (GATA3) for
Th2, FoxP3 for Treg, and Bcl6 for Tfh cells [9]. Although
angioimmunoblastic T-cell lymphomas (AITLs) originate
from Tfh cells, adult T-cell lymphoma/leukemia cells are
known to be derived from Treg cells [10,11]. Expression of
T-bet and GATA3 has been reported in PTCL-NOS cells; an
inferior prognosis is associated with the subtype overexpress-
ing GATA3 [12,13].
AlthoughRORγt expression in PTCL-NOShas only been stud-
ied in a small number of cases [8], its association with the clini-
copathological characteristics of PTCL-NOS has never been
investigated. In the present study, we examined the clinico-
pathological characteristics of RORγt-positive PTCL-NOS.
2. Materials and methods
2.1. Patients
We reviewed 170 cases of PTCL-NOS, including 62 cases
from the International Peripheral T-cell and Natural Killer/T-Fig. 1 Representative hematoxylin and eosin and immunohistochemical s
with 0%, 10%, 30%, and 60% RORγt expression are shown.cell Lymphoma Study [3], with a tissue microarray, and 108
cases diagnosed at Kurume University between 2005 and
2013. Some of these cases were included in our previous study
[14]. All cases were reviewed by experienced hematopatholo-
gists (O. K., M. H., and Y. E.) according to the World Health
Organization classification [2]. Clinical information was col-
lected in 75 cases by reviewing the patients' medical charts.
The study was approved by the Research Ethics Committee
of Kurume University and was conducted in accordance with
the Declaration of Helsinki.
2.2. Morphologic and immunohistochemical analysis
Each sample was investigated for its morphologic charac-
teristics according to our previous study [15]. Neoplastic T
cells were detected by assessing morphologic findings includ-
ing cell size and nuclear atypia. Nuclear atypia was evaluated
by some characteristics including pleomorphic nuclei of vary-
ing sizes, large nucleoli, and hyperchromatismwith coarse and
irregular distribution.
Immunohistochemical staining of formalin-fixed, paraffin-
embedded tissue sections was performed using an anti-RORγt
mouse monoclonal antibody (clone 6F3.1MABF81; Merck
Millipore, Darmstadt, Germany). We also used antibodies to
CD3 (clone LN10; Leica Biosystems, Newcastle, UK), CD4
(4B12; MBL, Nagoya, Japan), CD8 (4B11; Leica Biosys-
tems), CD30 (Ber-H2; Dako, Glostrup, Denmark), TIA1
(2G9A10F5; Beckman Coulter, Brea, CA), Granzyme B
(GrB-7; Chemicon, Temecula, CA), GATA3 (D13C9; Cell
Signaling Technology, Tokyo, Japan), and T-bet/Tbx21
(4B10; Abcam, Tokyo, Japan). Tumor cells with more than
30% staining were considered positive, and a case positive
for TIA1 and/or Granzyme B was considered cytotoxic mole-
cule positive. Cases with follicular helper T-cell phenotype
(Tfh markers) were defined if at least 2 antibodies againsttaining of RORγt in PTCL-NOS (original magnification ×400). Cases
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CXCL13, CD10, and BCL6, were positive.
2.3. In situ hybridization for Epstein-Barr virus–
encoded RNA
Epstein-Barr virus (EBV) was detected using in situ hybrid-
ization with a fluorescein-conjugated EBV peptide nucleic
acid probe kit (DakoCytomatin, Glostrup, Denmark), as de-
scribed previously [16].
2.4. Cutoff value determination for RORγt
The optimal cutoff value for RORγt expressionwas defined
on the basis of the receiver operating characteristic curve and
the Youden index [17], as well as previous studies [18]. In
the present study, the International Prognostic Index (IPI)
score, which has been recognized as a prognostic predictor
[19,20], was applied as a dichotomous variable, and RORγt
expression as a continuous variable. The Youden index re-
vealed an optimal cutoff value as 5% RORγt expression, and
cases with higher than 5% expression were defined as RORγt
positive (Fig. 1).
2.5. Statistical analysis
The clinical and pathological findings were compared using
the {chi}2 test, the Fisher exact test, or the Mann-Whitney U
test. The Kaplan-Meier method was used to estimate OS. A
log-rank test was used to compare the survival curves. A
Cox proportional hazards model was used to assess the prog-
nostic value of each factor. P values calculated in this studyTable 1 Comparison of pathological features between RORγt-positive
Characteristics T
Neoplastic cells
Clear cell, N30% 38
Cell size, large 54
CD4 positive, N30% 69
CD8 positive, N30% 21
TIA-1 and/or Granzyme B, N30% 40
CD30, N30% 20




N2 markers positive 3
Only 1 marker positive 21
Microenvironment
Infiltration of neutrophils, average/median [range] (counts/HPF) 1
Infiltration of eosinophils, average/median [range] (counts/HPF) 5
Infiltration of plasma cells, average/median [range] (counts/HPF) 3
Proliferation of HEV, average/median [range] (counts/HPF) 2
EBV (+) nonneoplastic cells, average/median [range] (counts/HPF) 1
Abbreviations: HPF, high-power field; HEV, high endothelial venules.
a Fisher exact test.were all based on 2-sided tests, and those less than .05 were
considered statistically significant. Statistical analysis in this
study was carried out using JMP, version 12 (SAS Institute,
Tokyo, Japan).3. Results
3.1. The proportion of neoplastic cells with RORγt ex-
pression in PTCL-NOS
As for the proportion of RORγt expression, less than 5%
neoplastic cells expressed RORγt in almost cases of PTCL-
NOS (Supplementary Fig. 1).
3.2. Pathological features
Table 1 shows a comparison of the pathological features of
170 RORγt-positive and RORγt-negative cases. There were
17.6% (30/170) RORγt-positive cases and 82.4% (140/170)
RORγt-negative cases. The RORγt-positive group showed
significantly higher CD8 positivity (P = .033), although the
other pathological characteristics did not show a significant
difference.
3.3. Clinical features
Table 2 summarizes the characteristics of the 75 pa-
tients with clinical information. Compared with the
RORγt-negative cases, the RORγt-positive cases showed
significantly lower counts of white blood cells (WBCs)PTCL-NOS and RORγt-negative PTCL-NOS
otal (n = 170) RORγt (+) (n = 30) RORγt (−) (n = 140) P
.8% (66/170) 46.7% (14/30) 37.1% (52/140) .335
.1% (92/170) 46.7% (14/30) 55.7% (78/140) .368
.2% (117/169) 70.0% (21/30) 69.1% (96/139) .920
.4% (36/168) 36.7% (11/30) 18.1% (25/138) .033
.0% (66/165) 50.0% (15/30) 37.8% (51/135) .220
.5% (24/117) 27.3% (6/22) 19.0% (18/95) .396
.7% (14/161) 3.5% (1/29) 9.9% (13/132) .468 a
.0% (34/170) 23.3% (7/30) 19.3% (27/140) .620
.2% (138/170) 90.0% (27/30) 79.3% (111/140) .207 a
.2% (2/62) 0% (0/12) 4.0% (2/50) 1.000 a
.0% (13/62) 25.0% (3/12) 20.0% (10/50) .703 a
.2/0 [0-46.4] 2.8/0 [0-46.4] 0.8/0 [0-30.2] .262
.5/0.4 [0-211] 2.5/0.4 [0-39.7] 6.2/0.4 [0-211] .952
.9/0.3 [0-87] 7.1/0.6 [0-50.3] 3.2/0.3 [0-87] .403
.2/1.6 [0-11.6] 2.1/1.7 [0.3-5.9] 2.3/1.6 [0-11.6] 1.000
.4/0 [0-51.4] 1.3/0 [0-16.9] 1.4/0 [0-51.4] .429
89RORγt in PTCL-NOS(P = .030) and neutrophils (P = .039), a higher incidence of
hypergammaglobulinemia (P = .031) and a better complete re-
sponse (CR) rate to the initial treatment (P = .009), and a ten-
dency for lower IPI scores (P = .061). The other clinical
factors did not show a significant difference between the 2
groups.
3.4. OS in PTCL-NOS patients based on RORγt
expression
Although not significant, RORγt-positive PTCL-NOS
showed a trend toward better OS compared with RORγt-neg-
ative cases (P = .0806; Fig. 2).
Univariate analyses identified the following variables as
prognostic factors (Table 3): a high IPI score (hazard ratio
[HR], 3.132; 95% confidence interval [CI], 1.626-6.174; P =
.0007), Ann Arbor stage III/IV (HR, 1.950; 95% CI, 1.024-
3.867; P = .0421), performance status (PS; HR, 6.896; 95%
CI, 3.412-14.468; P b .001), and B-symptoms (HR, 2.221;
95% CI, 1.170-4.325; P = .0147). However, RORγt positivityTable 2 Comparison of clinical features between RORγt-positive and R
Total (n = 75)
Characteristics
Sex, male/female 41/34
Age (y), average/median [range] 62.9/68 [6-87
Clinical findings
B-symptoms 45.3% (34/7
Raised rash 9.3% (7/75
Hepatomegaly 5.3% (4/75
Splenomegaly 13.3% (10/7
Skin infiltration 13.3% (10/7
Hemophagocytic syndrome 14.3% (9/63
Bone marrow involvement 16.2% (11/6
Extranodal involvement 53.3% (40/7
Ann Arbor stage, III or IV 53.3% (40/7
PS (2-4) 33.3% (25/7
IPI, high-risk group (3-5) 41.3% (31/7
PIT, high-risk group (3-4) 23.9% (16/6
Blood examination data
WBC, average/median [range] (×103 counts/μL) 6.5/5.7 [1-2
Neutrophil, average/median [range] (×103 counts/μL) 4.4/3.2 [1-1
Hemoglobin, average/median [range] (mg/dL) 12.0/12.1 [6.
Platelets, average/median [range] (×103 counts/μL) 213.8/204 [31
Hemolytic anemia 2.8% (2/71
Elevated LDH 49.3% (37/7
Hypergammaglobulinemia 18.0% (11/6
Elevated CRP 61.6% (45/7
Treatment
Treatment 94.7% (71/7
CHOP/CHOP like 79.2% (57/7
Initial radiotherapy 26.1% (6/23
Transplantation 6.7% (5/75
Recurrence 55.6% (35/6
Response to initial treatment, CR or CR(u) 40.3% (25/6
Abbreviations: PIT, Prognostic Index for T-cell lymphoma; CRP, C-reactive prote
complete response/remission; CR(u), uncertain complete response/remission.
a Fisher exact test.did not attain statistical significance (HR, 0.441; 95% CI,
0.150-1.036; P = .0612).
We conducted a multivariate analysis to evaluate the asso-
ciation of RORγt positivity with B-symptoms and constituents
of IPI, including age, Ann Arbor stage, PS, lactate dehydroge-
nase (LDH), and extranodal site (multivariate analysis 1). The
expression of RORγt was a significant prognostic factor (HR,
0.2969; 95% CI, 0.091-0.808; P = .0161). In contrast, when
we conducted multivariate analysis for RORγt positivity, B-
symptom, and IPI score (multivariate analysis 2), RORγt ex-
pression failed to reach statistical significance (HR, 0.420;
95% CI, 0.132-1.125; P = .0867).4. Discussion
In the present study, RORγt-positive PTCL-NOS cases
showed significantly a higher CR rate, hypergammaglobuline-
mia, lower WBC and neutrophil counts, and a tendency for
lower IPI scores and a good prognosis. Consistent withORγt-negative PTCL-NOS cases
RORγt (+) (n = 13) RORγt (−) (n = 62) P
8/5 33/29 .761 a
] 59.8/63.0 [6-79] 63.5/68.5 [12-87] .506
5) 46.2% (6/13) 45.2% (28/62) .948
) 7.7% (1/13) 9.7% (6/62) 1.000 a
) 0% (0/13) 6.5% (4/62) 1.000 a
5) 0% (0/13) 16.1% (10/62) .194 a
5) 15.4% (2/13) 12.9% (8/62) 1.000 a
) 18.2% (2/11) 13.5% (7/52) .650 a
8) 0% (0/11) 19.3% (11/57) .190 a
5) 46.2% (6/13) 54.8% (34/62) .569
5) 38.5% (5/13) 56.5% (35/62) .360 a
5) 23.1% (3/13) 35.5% (22/62) .524 a
5) 15.4% (2/13) 46.8% (29/62) .061 a
7) 9.1% (1/11) 26.8% (15/56) .275 a
9.3] 4.7/3.7 [2.0-12.1] 6.9/5.9 [1-29.3] .030
5.8] 2.3/2.3 [1.9-3.1] 4.9/3.8 [1-15.8] .039
8-16.4] 11.9/12.1 [8.7-14.4] 12.0/12.3 [6.8-16.4] .916
-548] 192.0/190.0 [56-323] 218.4/218.5 [31-548] .437
) 0% (0/12) 3.4% (2/59) 1.000 a
5) 46.2% (6/13) 50.0% (31/62) .801
1) 41.7% (5/12) 12.2% (6/49) .031 a
3) 46.2% (6/13) 65.0% (39/60) .211
5) 100% (13/13) 93.6% (58/62) 1.000 a
2) 69.2% (9/13) 81.4% (48/59) .450 a
) 40.0% (2/5) 22.2% (4/18) .576 a
) 7.7% (1/13) 6.5% (4/62) 1.000 a
3) 58.3% (7/12) 54.9% (28/51) 1.000 a
2) 75.0% (9/12) 32.0% (16/50) .009 a
in; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR,
Fig. 2 Kaplan-Meier curves for OS for PTCL-NOS cases according to RORγt expression. OS of cases with at least 5% RORγt expression was
better than of cases with less than 5% RORγt expression (P = .0806).
Table 3 Prognostic factors affecting the OS of patients with PTCL-NOS
Characteristics Univariate analysis Multivariate analysis 1 a Multivariate analysis 2 b
HR (95% CI) P HR (95% CI) P HR (95% CI) P
RORγt, positive (vs RORγt, negative) 0.441 (0.150-1.036) .0612 0.2969 (0.091-0.808) .0161 0.420 (0.132-1.125) .0867
PS, 2-4 (vs 0 or 1) 6.896 (3.412-14.468) b.001 7.364 (3.263-17.558) b.001
Age, N60 y (vs b60 y) 1.140 (0.596-2.290) .6981 0.590 (0.271-1.310) .1908
Ann Arbor stage, III/IV (vs I/II) 1.950 (1.024-3.867) .0421 1.264 (0.563-2.897) .5710
Extranodal sites ≥2 (vs b2) 1.997 (0.972-3.871) .0475 0.998 (0.410-2.331) .9972
LDH, elevated (vs normal) 1.352 (0.717-2.576) .3508 0.981 (0.491-1.968) .9563
B-symptom present (vs absent) 2.221 (1.170-4.325) .0147 2.376 (1.149-5.014) .0196 2.809 (1.424-5.737) .0028
Cytotoxic molecule positive (vs negative) 1.754 (0.931-3.338) .0816 1.864 (0.906-3.874) .0904 2.130 (1.077-4.272) .0299
IPI, high (vs low) 3.132 (1.626-6.174) .0007 2.727 (1.367-5.625) .0043
a The variables included in multivariate analysis 1 for OS were age, Ann arbor stage, PS, LDH, B-symptom, cytotoxic molecule, and the expression of
RORγt.
b The variables included in the second multivariate analysis 2 for OS were IPI, cytotoxic molecules, and the expression of RORγt.
90 E. Yanagida et al.previous reports [19,20], our study indicates that a tendency
for low IPI score is a good prognostic factor for PTCL-NOS,
which also indicates that our cohort is devoid of any selection
bias. The RORγt-positive PTCL-NOS group, characterized by
a high CR rate in response to the initial treatment, hypergam-
maglobulinemia, low counts ofWBC and neutrophils, and ten-
dency for lower IPI scores and a good prognosis, may
therefore comprise a new subtype.
So far, several studies have reported an association between
prognosis and RORγt expression in neoplastic cells or tumor-
infiltrating lymphocytes (TILs). RORγt can act as key tran-
scription factor for the development of Th17 cells also in
mouse [3]. The analysis of RORγt-knockout mice disclosed
that these mice develop the T-cell lymphoma, although the un-
derlying mechanism remains unclear [21]. On the other hand,
it has been reported that high expression of RORγt in TILs is a
risk factor for lymph node metastasis and is an independent
poor prognostic factor for OS in colon cancer [7]. Th17 cells
that are regulated by RORγt, as well as cytokines such as inter-
leukin-6 (IL-6) and transforming growth factor β, induce the
production of proinflammatory cytokines IL-17, IL-22, andtumor necrosis factor α. Chronic and recurrent inflammation
induced by these cytokines can lead to carcinogenesis by in-
ducing genome instability and increasing the potential for tu-
mor cell growth and angiogenesis [7]. Unlike in TILs,
RORγt expression has been reported to be associated with a
good prognosis in malignant melanoma [22], although the un-
derlying mechanism is not clear. In this study of PTCL-NOS,
the RORγt expression observed in the tumor cells was associ-
ated with a better prognosis than that seen in malignant mela-
noma, whereas low expression of RORγt was seen in TILs
(data not shown). Studies to understand the mechanisms are
required in the future.
The RORγt-positive group had significantly higher levels
of hypergammaglobulinemia and low counts of WBCs and
neutrophils. Studies have shown that naïve helper CD4+ T
cells differentiate into the Th17 lineage under the regulation
of RORγt, with simultaneous stimulation from IL-6 and trans-
forming growth factor β [4]. Th17 cells produce not only IL-17
but also IL-6 [4]. Stimulation by IL-6 induces the differentia-
tion of antibody-producing plasma cells, which may result in
hypergammaglobulinemia [4,23,24]. Studies with transgenic
91RORγt in PTCL-NOSmice have shown that RORγt overexpression causes an eleva-
tion in IL-6 levels, leading to polyclonal plasmacytosis, and an
increased antibody production, resulting in hypergammaglo-
bulinemia [25,26]. These reports suggest a potential role of
Th17 cells in the hypergammaglobulinemia observed in
RORγt-positive PTCL NOS.
RORγt-positive PTCL-NOS cases showed clear cells in
half of the cases as well as hypergammaglobulinemia, which
are characteristics of AITL. We compared RORγt-positive
PTCL-NOS with AITL (Supplementary Table 1) clinicopath-
ologically, using data from our previous studies [16]. Statisti-
cal differences, based on clinicopathological findings
between RORγt-positive PTCL-NOS and AITL, have been
shown, although no significant difference in prognosis was ob-
served. These differences suggested that RORγt-positive
PTCL-NOS and AITL might be another disease entity.
In this study, patients with RORγt-positive PTCL-NOS
showed a significantly higher proportion of CD8-positive
cells, although no association among the expression of RORγt,
CD4, CD8, and cytotoxic molecules was detected (data not
shown). Double staining of RORγt and CD8 (Supplementary
Fig. 2) showed that some neoplastic cells had only CD8 ex-
pression and some had only ROR-γt, whereas the rest had both
RORγt and CD8 expression. Neoplastic cells actually showed
various expression patterns of RORγt and CD8. Patients with
RORγt-positive PTCL-NOS showed a significantly higher
proportion of CD8-positive cells compared with those with
RORγt-negative PTCL-NOS. However, CD4 expression was
also observed in most of the cases (70%) in both RORγt-neg-
ative and RORγt-positive groups, regardless of CD8 expres-
sion. Whether the expression of CD4 or CD8 in RORγt-
positive neoplastic cells corresponds to the nature of neoplastic
cell origin is yet to be clarified. In addition, the significance of
CD8 expression in RORγt-positive PTCL-NOS remains un-
known and should be explored in the future.
On the other hand, RORγt is considered a major tran-
scription factor for Th17 cells. The RORγt is necessary for
the differentiation of naïve CD4+ helper T cells into Th17
cells [4]. This study suggests the possibility that Th17 might
be the derived cells of RORγt-positive PTCL-NOS, because
RORγt is a transcription factor for Th17 cells and RORγt-pos-
itive PTCL-NOS expressed CD4 in most of the cases, al-
though it is difficult to confirm derived cells based on RORγt
expression only.
Solt et al [27] have reported a synthetic RORγt ligand that
inhibits the differentiation of Th17 and has been used in the
treatment of autoimmune diseases. Huh et al [28] reported that
derivatives of digoxin can be used as therapeutic agents to tar-
get RORγt and attenuate inflammatory lymphocyte functions
in autoimmune diseases. Targeting the RORγt might be an ef-
fective treatment for RORγt-positive PTCL-NOS.
In conclusion, PTCL-NOS patients with and without
RORγt expression showed different clinicopathological traits,
suggesting that RORγt-positive PTCL-NOS could be a sub-
type of PTCL-NOS. Larger cohort studies are needed to con-
firm the results of this study.Supplementary data
Supplementary data to this article can be found online at
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